. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: Kidney Int. 2019 Feb 19;95(5):1262–1268. doi: 10.1016/j.kint.2018.11.024

Table 1.

Baseline Characteristics

	Placebo	Pioglitazone

Number of subjects	18	18
Age, years	55.2 ± 11.2	58.9 ± 9.1
Gender (F/M)	6 / 12	7 / 11
Race (Black/White)	3 / 15	2 / 16
Ethnicity (Hispanic/Non-Hispanic)	5 / 13	2 / 16
Type 2 Diabetes (Yes/No)	5 / 13	10 / 8
Serum chemistry
Na, mmoles/L	138 ± 2	137 ± 2
K, mmoles/L	4.4 ± 0.3	4.4 ± 0.4
Cl, mmoles/L	105 ± 2	104 ± 3
CO₂, mmoles/L	25 ± 3	24 ± 3
Ca, mmoles/L	2.31 ± 0.05	2.32 ± 0.10
Albumin, g/L	413 ± 19	414 ± 27
BUN, mmoles/L	5.6 ± 1.8	6.0 ± 1.8
Creatinine, μmoles/L	94 ± 33	92 ± 27

Data shown as mean ± standard deviation